Spots Global Cancer Trial Database for Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Official Title: Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Study ID: NCT01219192
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.
Detailed Description: To evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.We star with the dose M2ES 15mg,then escalate to 30mg 45mg 60mg,to find the recommended dose in clinic practise.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Contact Details
Name: Shunchang JIAO, MD
Affiliation: Chinese PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
